RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough.

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

For refractory chronic cough or unexplained chronic cough, gefapixant 45 mg twice per day is the first treatment to show efficacy with an acceptable safety profile in phase 3 clinical trials.

New study by Lorcan P McGarvey & colleagues: https://t.co/XnWM75s6lN pic.twitter.com/VyYyRgWTod

— The Lancet (@TheLancet) March 7, 2022